Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)

10 november 2026 uppdaterad av: Zuzana Jirásková, General University Hospital, Prague

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

Studieöversikt

Detaljerad beskrivning

Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.

Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.

The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.

Studietyp

Interventionell

Inskrivning (Beräknad)

47

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Prague, Tjeckien, 128 08
        • Rekrytering
        • General University Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

7 år till 12 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Children aged 7 to 12 years, boys and girls
  • Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
  • At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
  • No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
  • Ability and willingness of the child and the parent to follow the protocol; signed informed consent

Exclusion Criteria:

  • Severe daytime incontinence (complete wetting in more than 50% of episodes)
  • Anticholinergic treatment for overactive bladder in the last 3 months
  • Neurogenic lower urinary tract dysfunction
  • Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
  • Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
  • Local lesions of the lower limbs (skin disease, osteosynthesis material)
  • Peripheral neuropathy of the lower limbs
  • Presence of an electronic implant in the body (e.g., a neurostimulator)
  • Functional constipation during the previous 3 months (Rome III-IV criteria)
  • Symptomatic urinary tract infection

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Active stimulation

Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.

Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

Sham Comparator: Sham stimulation

Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.

Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of clinical responders at the end of treatment
Tidsram: Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

A clinical responder is a child who meets either or both of the following criteria at the end of treatment:

  1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline;
  2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in the number of daytime incontinence episodes per 24 hours
Tidsram: Baseline, Week 6, Week 12

Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the severity of daytime incontinence episodes
Tidsram: Baseline, Week 6, Week 12

Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the number of wet days
Tidsram: Baseline, Week 6, Week 12

Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.

Baseline, Week 6, Week 12
Change in micturition frequency and functional bladder capacity
Tidsram: Baseline, Week 6, Week 12

Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.

Baseline, Week 6, Week 12
Change in DVISS total score (parent-rated)
Tidsram: Baseline, Week 6, Week 12

Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.

Baseline, Week 6, Week 12
Change in Bower PIN-Q total score (child-rated)
Tidsram: Baseline, Week 6, Week 12

Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.

Baseline, Week 6, Week 12
PGI-I score rated by the child and by the parent
Tidsram: Week 6, Week 12

Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).

Week 6, Week 12
CGI-I score rated by the unblinded investigator
Tidsram: Week 6, Week 12

Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).

Week 6, Week 12
Number, type and severity of treatment-related adverse events
Tidsram: From the first stimulation to Week 12

Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.

From the first stimulation to Week 12
Adherence to treatment
Tidsram: Week 12

Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.

Week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Zuzana Jiraskova, MD, FEAPU, General University Hospital, Prague

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 september 2026

Primärt slutförande (Beräknad)

1 juni 2028

Avslutad studie (Beräknad)

1 juni 2028

Studieregistreringsdatum

Först inskickad

10 november 2026

Först inskickad som uppfyllde QC-kriterierna

10 november 2026

Första postat (Faktisk)

16 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • Uris_01_2026
  • 000058 (Annan identifierare: ISZP)
  • sukls114680/2026 (Annan identifierare: State Institute for Drug Control (SUKL))
  • sukl222573/2026 (Annan identifierare: State Institute for Drug Control (SUKL))
  • 376/26 A, IB, D, PS (Annan identifierare: Ethics Committee, General University Hospital in Prague)
  • 443/26 A, IB (Annan identifierare: Ethics Committee, General University Hospital in Prague)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera